Multiple Myeloma

Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene autoleucel (cilta-cel) Out-of-Specification (OOS) in patients with Multiple Myeloma

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

Reaching Rural Cancer Survivors Who Smoke Using Test-Based Cessation Interventions

Expanded Access Protocol (EAP) for Subjects Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release

A Phase 3, Open-Label Study of Elranatamab Monotherapy versus Elotuzumab, Pomalidomide, Dexamethasone (EPd) or Pomalidomide, Brotezomib, Dexamethasone 9PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed/Refractory Multiple Myeloma who Received Prior Anti-CD38 Directed Therapy

Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma

Molecular Analysis for Combination Therapy Choice (ComboMATCH)

A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

Expanded Access Protocol (EAP) for Subjects Receiving Lisocabtagene Maraleucel that is Nonconforming for Commercial Release

Expanded access to commercially out-of-specification brexucabtagene autoleucel for the treatment of adult patients diagnosed with an FDA approved labeled indication

Prospective Evaluation of Xerava (Eravacycline) Prophylaxis in Hematological Malignancy Patients with Prolonged Neutropenia